Ranjiv Choudhary, MD
Cardiology · Palmdale, CANPI 1790746014
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,479 of the $6,650 with a category attached, or 82.4%. 37 manufacturers reported payments, led by Medtronic at 26.3% of the total.
Across 232 payments — averaging $28.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- AstraZeneca$572
- Boston Scientific$517
- Pfizer$485
- Merck$406
- Amgen$366
- plus $3K from 31 others
What the payments were for
- Travel & lodging$1,11417%
- Food & beverage$5,47982%
- Education$571%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 14 | $1,750 |
| AstraZeneca | 33 | $572 |
| Boston Scientific | 16 | $517 |
| Pfizer | 30 | $485 |
| Merck | 18 | $406 |
| Amgen | 12 | $366 |
| Novartis | 16 | $324 |
| Shockwave Medical, Inc | 2 | $267 |
| Abbott | 11 | $267 |
| Boehringer Ingelheim | 12 | $263 |
| Kowa Pharmaceuticals America, Inc. | 8 | $164 |
| Johnson & Johnson | 8 | $151 |
| Esperion Therapeutics, Inc. | 7 | $138 |
| Biosense Webster, Inc. | 1 | $119 |
| Stryker | 4 | $97 |
| Alnylam Pharmaceuticals Inc. | 4 | $75 |
| Bayer | 3 | $67 |
| Novo Nordisk | 3 | $52 |
| Biotronik Inc. | 3 | $50 |
| Scpharmaceuticals Inc. | 3 | $49 |
| E.r. Squibb & Sons, L.L.C. | 3 | $48 |
| Lexicon Pharmaceuticals, Inc. | 2 | $45 |
| Aegerion Pharmaceuticals, Inc. | 2 | $42 |
| Actelion Pharmaceuticals US, Inc. | 2 | $37 |
| Eisai Inc. | 2 | $37 |
| Inari Medical, Inc. | 1 | $36 |
| Cardiovascular Systems Inc. | 2 | $28 |
| AbbVie | 1 | $24 |
| Lundbeck LLC | 1 | $24 |
| Radius Health, Inc. | 1 | $22 |
| Lilly USA, LLC | 1 | $22 |
| Convatec Inc. | 1 | $21 |
| Vifor Pharma, Inc. | 1 | $20 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $19 |
| Abiomed | 1 | $19 |
| Heartflow, Inc. | 1 | $15 |
| Regeneron Healthcare Solutions, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,650 in reported general payments places this provider in the 85th percentile of 156 cardiology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 315 | $396,481 |
| EntrestoSacubitril/Valsartan | 131 | $171,551 |
| XareltoRivaroxaban | 83 | $116,674 |
| OzempicSemaglutide | 65 | $98,783 |
| JardianceEmpagliflozin | 81 | $91,913 |
| Repatha SureclickEvolocumab | 82 | $78,594 |
| BrilintaTicagrelor | 75 | $60,267 |
| FarxigaDapagliflozin Propanediol | 61 | $57,793 |
| RybelsusSemaglutide | 27 | $50,292 |
| MounjaroTirzepatide | 33 | $34,060 |
| VascepaIcosapent Ethyl | 53 | $32,865 |
| Praluent PenAlirocumab | 27 | $22,786 |
| JanuviaSitagliptin Phosphate | 20 | $21,020 |
| TrulicityDulaglutide | 15 | $16,335 |
| KerendiaFinerenone | 12 | $7,248 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $485 | $396,481315 claims |
| NovartisEntresto | $324 | $171,551131 claims |
| Novo NordiskOzempic, Rybelsus | $52 | $149,07592 claims |
| AstraZenecaBrilinta, Farxiga | $572 | $118,060136 claims |
| Johnson & JohnsonXarelto | $151 | $116,67483 claims |
| Boehringer IngelheimJardiance | $263 | $91,91381 claims |
| Lilly USA, LLCMounjaro, Trulicity | $22 | $50,39548 claims |
| MerckJanuvia | $406 | $21,02020 claims |
| BayerKerendia | $67 | $7,24812 claims |
| AbbVieSynthroid | $24 | $2,65233 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 156 cardiology providers in California.
Other cardiology in Palmdale
- Norman LeporBeverly Hills$1.9M
- Sanjay KaulLos Angeles$1.1M
- Ramtin AgahMountain View$361K
- Jamshid MaddahiLos Angeles$59K
- Bipin JoshiFresno$51K
- Anil ShahSanta Ana$49K
- Thomas KimSanta Ana$47K
- Hooman MadyoonLos Angeles$24K
- Lakhjit SandhuFresno$19K
- Prabhtej BraraSanta Monica$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.